Publications

Frank Lieberman, MD

Lieberman FS, Wang M, Robins HI, Tsien CI, Curran WJ Jr, Werner-Wasik M, Smith RP, Schultz C, Hartford AC, Zhang P, Mehta MP. Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420. Int J Radiat Oncol Biol Phys. 2019 Mar 15;103(4):878-886. doi: 10.1016/j.ijrobp.2018.11.008. PubMed PMID: 30496882.
Dressen MS, Muthukrishnan A, Tragon TR, Lieberman FS, Mountz JM. Complementary Molecular and Metabolic Characterization of Meningiomas With DOTATATE and FDG-PET: Advancing Treatment Planning and Prognostication. Clin Nucl Med. 2019 Jan;44(1):e26-e27. doi: 10.1097/RLU.0000000000002328. PubMed PMID: 30371576.
Mantica M, Pritchard A, Lieberman F, Drappatz J. Retrospective study of nivolumab for patients with recurrent high grade gliomas. J Neurooncol. 2018 Sep;139(3):625-631. doi: 10.1007/s11060-018-2907-4. PubMed PMID: 29779086.
Blumenthal DT, Won M, Mehta MP, Gilbert MR, Brown PD, Bokstein F, Brachman DG, Werner-Wasik M, Hunter GK, Valeinis E, Hopkins K, Souhami L, Howard SP, Lieberman FS, Shrieve DC, Wendland MM, Robinson CG, Zhang P, Corn BW. Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database. Neuro Oncol. 2018 Jun 18;20(7):966-974. doi: 10.1093/neuonc/noy017. PubMed PMID: 29462493; PMCID: PMC6007748.
Lieberman F. Glioblastoma update: molecular biology, diagnosis, treatment, response assessment, and translational clinical trials. F1000Res. 2017;61892. doi: 10.12688/f1000research.11493.1. PubMed PMID: 29263783; PMCID: PMC5658706.
Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017 Dec 19;318(23):2306-2316. doi: 10.1001/jama.2017.18718. PubMed PMID: 29260225; PMCID: PMC5820703.
Schirda CV, Zhao T, Yushmanov VE, Lee Y, Ghearing GR, Lieberman FS, Panigrahy A, Hetherington HP, Pan JW. Fast 3D rosette spectroscopic imaging of neocortical abnormalities at 3 T: Assessment of spectral quality. Magn Reson Med. 2018 May;79(5):2470-2480. doi: 10.1002/mrm.26901. PubMed PMID: 28905419; PMCID: PMC5821598.
Tonetti DA, Ares WJ, Richardson RM, Hamilton RL, Lieberman FS. Long-term recurrence of dysembryoplastic neuroepithelial tumor: Clinical case report. Surg Neurol Int. 2017;8140. doi: 10.4103/2152-7806.210257. PubMed PMID: 28781917; PMCID: PMC5523508.
Boele FW, van Uden-Kraan CF, Hilverda K, Weimer J, Donovan HS, Drappatz J, Lieberman FS, Verdonck-de Leeuw I, Sherwood PR. Neuro-oncology family caregivers' view on keeping track of care issues using eHealth systems: it's a question of time. J Neurooncol. 2017 Aug;134(1):157-167. doi: 10.1007/s11060-017-2504-y. PubMed PMID: 28550505; PMCID: PMC5543187.
Holdhoff M, Ye X, Supko JG, Nabors LB, Desai AS, Walbert T, Lesser GJ, Read WL, Lieberman FS, Lodge MA, Leal J, Fisher JD, Desideri S, Grossman SA, Wahl RL, Schiff D. Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. Neuro Oncol. 2017 Jun 1;19(6):845-852. doi: 10.1093/neuonc/nox020. PubMed PMID: 28371832; PMCID: PMC5464434.
Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, Chen A, Grossman S, Prados M, Wen PY. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. J Neurooncol. 2017 Mar;132(1):181-188. doi: 10.1007/s11060-016-2357-9. PubMed PMID: 28116649; PMCID: PMC5588922.
Oborski MJ, Laymon CM, Lieberman FS, Qian Y, Drappatz J, Mountz JM. [18F]ML-10 PET: Initial Experience in Glioblastoma Multiforme Therapy Response Assessment. Tomography. 2016 Dec;2(4):317-324. doi: 10.18383/j.tom.2016.00175. PubMed PMID: 30042965; PMCID: PMC6037921.
Boele FW, Given CW, Given BA, Donovan HS, Schulz R, Weimer JM, Drappatz J, Lieberman FS, Sherwood PR. Family caregivers' level of mastery predicts survival of patients with glioblastoma: A preliminary report. Cancer. 2017 Mar 1;123(5):832-840. doi: 10.1002/cncr.30428. PubMed PMID: 27787881; PMCID: PMC5319890.
Lodge MA, Holdhoff M, Leal JP, Bag AK, Nabors LB, Mintz A, Lesser GJ, Mankoff DA, Desai AS, Mountz JM, Lieberman FS, Fisher JD, Desideri S, Ye X, Grossman SA, Schiff D, Wahl RL. Repeatability of 18F-FLT PET in a Multicenter Study of Patients with High-Grade Glioma. J Nucl Med. 2017 Mar;58(3):393-398. doi: 10.2967/jnumed.116.178434. PubMed PMID: 27688473; PMCID: PMC5331936.
Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, Jones DT, Luu B, Cavalli FM, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon RE, Lipp ES, Dunham C, Hukin J, Eisenstat DD, Fulton D, van Landeghem FK, Santi M, van Veelen ML, Van Meir EG, Osuka S, Fan X, Muraszko KM, Tirapelli DP, Oba-Shinjo SM, Marie SK, Carlotti CG, Lee JY, Rao AA, Giannini C, Faria CC, Nunes S, Mora J, Hamilton RL, Hauser P, Jabado N, Petrecca K, Jung S, Massimi L, Zollo M, Cinalli G, Bognár L, Klekner A, Hortobágyi T, Leary S, Ermoian RP, Olson JM, Leonard JR, Gardner C, Grajkowska WA, Chambless LB, Cain J, Eberhart CG, Ahsan S, Massimino M, Giangaspero F, Buttarelli FR, Packer RJ, Emery L, Yong WH, Soto H, Liau LM, Everson R, Grossbach A, Shalaby T, Grotzer M, Karajannis MA, Zagzag D, Wheeler H, von Hoff K, Alonso MM, Tuñon T, Schüller U, Zitterbart K, Sterba J, Chan JA, Guzman M, Elbabaa SK, Colman H, Dhall G, Fisher PG, Fouladi M, Gajjar A, Goldman S, Hwang E, Kool M, Ladha H, Vera-Bolanos E, Wani K, Lieberman F, Mikkelsen T, Omuro AM, Pollack IF, Prados M, Robins HI, Soffietti R, Wu J, Metellus P, Tabori U, Bartels U, Bouffet E, Hawkins CE, Rutka JT, Dirks P, Pfister SM, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Ellison DW, Taylor MD. Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. J Clin Oncol. 2016 Jul 20;34(21):2468-77. doi: 10.1200/JCO.2015.65.7825. PubMed PMID: 27269943; PMCID: PMC4962737.
Yankeelov TE, Mankoff DA, Schwartz LH, Lieberman FS, Buatti JM, Mountz JM, Erickson BJ, Fennessy FM, Huang W, Kalpathy-Cramer J, Wahl RL, Linden HM, Kinahan PE, Zhao B, Hylton NM, Gillies RJ, Clarke L, Nordstrom R, Rubin DL. Quantitative Imaging in Cancer Clinical Trials. Clin Cancer Res. 2016 Jan 15;22(2):284-90. doi: 10.1158/1078-0432.CCR-14-3336. PubMed PMID: 26773162; PMCID: PMC4717912.
Nikiforova MN, Wald AI, Melan MA, Roy S, Zhong S, Hamilton RL, Lieberman FS, Drappatz J, Amankulor NM, Pollack IF, Nikiforov YE, Horbinski C. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors. Neuro Oncol. 2016 Mar;18(3):379-87. doi: 10.1093/neuonc/nov289. PubMed PMID: 26681766; PMCID: PMC4767245.
Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA. 2015 Dec 15;314(23):2535-43. doi: 10.1001/jama.2015.16669. PubMed PMID: 26670971.

<< Investigators Search

Top